- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | CMBI Raises SKB BIO TP to HKD645.62 as Latest TROP2 ADC Progress Strengthens Global Positioning of sac-TMT | 1 | AASTOCKS | ||
| 04.11. | SKB BIO (06990): DISCLOSEABLE TRANSACTION SUBSCRIPTIONS FOR WEALTH MANAGEMENT PRODUCTS | 2 | HKEx | ||
| 02.11. | Citi: China Pharma and Biotech ESMO Data Further Validated; Favors CSPC PHARMA, HENGRUI PHARMA, INNOVENT BIO and SKB BIO | 13 | AASTOCKS | ||
| 29.10. | Sichuan Kelun Pharmaceutical Co., Ltd. Nine Months Income Advances | 1 | RTTNews | ||
| 27.10. | Kelun-Biotech: New Indication Application for Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab as First-Line Treatment for PD-L1-Negative Non-Squamous NSCLC Accepted for Review by NMPA | 385 | PR Newswire | This is the seventh indication application for sacituzumab tirumotecan (sac-TMT) and the second application for the ADC plus IO combination regimen of sac-TMT plus pembrolizumab accepted for review.The... ► Artikel lesen | |
| 27.10. | SKB BIO Core Product TROP2 ADC Receives China Acceptance for Additional Indication | 1 | AASTOCKS | ||
| SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL Aktie jetzt für 0€ handeln | |||||
| 27.10. | SKB BIO (06990): VOLUNTARY ANNOUNCEMENT NEW INDICATION APPLICATION FOR CORE PRODUCT TROP2 ADC SACITUZUMAB TIRUMOTECAN (SAC-TMT) ACCEPTED BY THE NATIONAL ... | 1 | HKEx | ||
| 26.10. | UBS: SKB BIO OptiTROP-L06 Data Show Best-in-class Potential | 2 | AASTOCKS | ||
| 26.10. | Jefferies: SKB BIO sac-TMT First-line Lung Cancer Data Strong | 1 | AASTOCKS | ||
| 26.10. | CLSA Says US Proposed Ban on Outbound Investment in Biotech Has Limited Impact; Rates SKB BIO Outperform | 1 | AASTOCKS | ||
| 25.10. | ESMO: Merck, Kelun's 'workhorse' ADC posts major tumor progression benefit in PD-L1-negative NSCLC | 9 | FiercePharma | ||
| 17.09. | SKB BIO (06990): 2026 INTERIM REPORT | 2 | HKEx | ||
| 14.09. | Kelun-Biotech: Results from Phase III Study of Trastuzumab Botidotin versus T-DM1 in HER2-Positive Breast Cancer Published in JCO | 397 | PR Newswire | CHENGDU, China, Sept. 14, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or "the Company", 6990.HK) announced that results from the phase III registrational... ► Artikel lesen | |
| 08.09. | Kelun-Biotech's Partner Windward Bio Announces Positive Phase 2 Results of SKB378/WIN378 in Asthma, and Initiates Phase 3 Study | 228 | PR Newswire | The POLARIS-1 study enrolled 147 patients with uncontrolled, moderate-to-severe asthma, and the interim analysis was conducted on the first 98 patients. The analysis... ► Artikel lesen | |
| 08.09. | SKB BIO (06990): VOLUNTARY ANNOUNCEMENT POSITIVE PHASE 2 INTERIM RESULTS AND INITIATION OF PHASE 3 STUDY OF SKB378/WIN378 IN ASTHMA | - | HKEx | ||
| 27.08. | Cancer Drug Sales Power Up Kelun-Biotech's Profit Engine | 2 | Benzinga.com | ||
| 27.08. | Sichuan Kelun Pharmaceutical Co., Ltd. H1 Income Rises | 1 | RTTNews | ||
| 17.08. | Kelun-Biotech H1 2026 presentation: commercialization revenue surges 112% | 2 | Investing.com | ||
| 17.08. | Kelun-Biotech Announces 2026 Interim Results | 455 | PR Newswire | CHENGDU, China, Aug. 17, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", Stock Code: 6990.HK) announces its unaudited consolidated... ► Artikel lesen | |
| 17.08. | SKB BIO (06990): INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2026 | - | HKEx |
1 2 3 Weiter >>
57 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 45,300 | +0,13 % | QIAGEN N.V.: QIAGEN-Aktionäre stimmen der Berufung von Jonathan M. Pratt in die Geschäftsführung mit überwältigender Mehrheit zu | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) hat heute bekannt gegeben, dass die Aktionärinnen und Aktionäre auf einer Außerordentlichen Hauptversammlung der Berufung von Jonathan M. Pratt... ► Artikel lesen | |
| MBX BIOSCIENCES | 55,94 | 0,00 % | Citizens reiterates MBX Biosciences stock rating on GLP agonist data | ||
| ERASCA | 15,655 | -0,03 % | Erasca GAAP EPS of -$0.15 misses by $0.01 | ||
| TANGO THERAPEUTICS | 25,500 | 0,00 % | Jefferies raises Tango Therapeutics stock price target on trial data | ||
| VIR BIOTECHNOLOGY | 9,970 | +0,10 % | Vir Biotechnology: HDV-Daten lassen Aktie explodieren | Vir Biotechnology sorgt mit gleich zwei positiven Nachrichten im Bereich Hepatitis Delta für Aufsehen. Sowohl die ersten Ergebnisse der zulassungsrelevanten Phase-3-Studie als auch erweiterte Phase-2-Daten... ► Artikel lesen | |
| CG ONCOLOGY | 74,36 | -0,05 % | CG Oncology Inc.: CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates | PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC anticipated in the near-termBLA completion for HR BCG-unresponsive NMIBC expected... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 14,140 | -0,07 % | Summit Therapeutics: Ivonescimab Plus Chemotherapy Demonstrates Overall Survival Superiority Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer in HARMONi-GI1 Study Conducted by Akeso in China | First Regimen to Achieve a Statistically Significant and Clinically Meaningful Overall Survival Benefit over an Anti-PD-(L)1 Antibody Combined with Chemotherapy in a Phase III Clinical Trial in... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 327,68 | -0,14 % | Praxis Precision Medicines stellt Markteinführungspläne für zwei Medikamentenkandidaten vor | ||
| RELAY THERAPEUTICS | 18,090 | 0,00 % | Relay Therapeutics, Inc.: Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates | Selected zovegalisib plus atirmociclib as go-forward triplet regimen for 1L breast cancer; Phase 3 1L trial in endocrine- sensitive patients expected to initiate in early 2027, subject to regulatory... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 48,810 | +0,02 % | Enliven Therapeutics, Inc.: Enliven Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Business Update | Reached alignment with the FDA on the final design of the ENABLE-2 pivotal Phase 3 trial On track to initiate ENABLE-2 before year-end 2026 Strong balance sheet with $884 million in cash, cash equivalents... ► Artikel lesen | |
| ADMA BIOLOGICS | 13,690 | 0,00 % | Kehoe Law Firm, P.C.: ADMA Biologics (ADMA) Shareholder Alert: Kehoe Law Firm Investigates Potential Fiduciary Duty Breaches | Philadelphia, Pennsylvania--(Newsfile Corp. - August 5, 2026) - Kehoe Law Firm, P.C. is investigating whether certain officers and directors of ADMA Biologics, Inc. ("ADMA," "ADMA Biologics," or... ► Artikel lesen | |
| ABSCI | 8,440 | -0,12 % | Absci anticipates interim 13-week ABS-201 pattern hair loss data next month as it plans mid-2027 endometriosis Phase 2 start | ||
| PRIME MEDICINE | 4,270 | 0,00 % | Prime Medicine closes $143.7M public offering at $3.50/share | ||
| AMYLYX PHARMACEUTICALS | 30,300 | +0,03 % | Amylyx: Avexitide-Studie erreicht primären Endpunkt bei postbariatrischer Hypoglykämie | ||
| PARABILIS MEDICINES | 28,430 | 0,00 % | Liberty Defense zahlt Darlehen über 2,45 Millionen US-Dollar an Parabilis vollständig zurück |
Das Unternehmen SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO LTD kann der Branche Biotechnologie zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO LTD finden Sie auf Wallstreet Online.